Global Lamivudine Market 2023-2030

    In Stock

    Coming Soon




    An antiviral drug called lamivudine is used to treat viral illnesses like hepatitis B and HIV/AIDS. It is a member of the class of medications known as nucleoside reverse transcriptase inhibitors (NRTIs), which prevent viruses from replicating by inhibiting the reverse transcriptase enzyme.


     When treating HIV/AIDS, lamivudine is frequently taken in combination with other drugs. It can also be used to treat chronic hepatitis B virus infection, either by itself or in conjunction with other medications. The drug is offered as a pill and a liquid, and it is normally used once or twice day, as prescribed by a doctor.


    Lamivudine can have side effects, like any medicines, albeit not everyone gets them. Headache, nauseousness, diarrhea, and weariness are typical adverse reactions.


    Patients taking lamivudine should be constantly watched for any signs of liver damage because it can, in rare instances, cause severe liver problems. Lamivudine is taken by mouth as a tablet or a liquid.


    A doctor must decide the lamivudine dose, which is based on body weight. The typical dosage is either 10 mg per kg once day.or 5 milligrammes (mg) per kilogramme (kg) of body weight taken twice daily.


    The dose may be increased by the doctor as necessary, but it typically does not exceed 300 mg per day when combined with other HIV medications. Always combine lamivudine with another HIV medication.




    infographic: Lamivudine Market, Lamivudine Market Size, Lamivudine Market Trends, Lamivudine Market Forecast, Lamivudine Market Risks, Lamivudine Market Report, Lamivudine Market Share


    Global Lamivudine market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.



    A drug called lamivudine is used to treat HIV-1 and chronic hepatitis B infections. Dovato, a full treatment regimen for HIV-1 infection in people without a history of antiretroviral therapy and without any known or suspected alterations linked to resistance to either dolutegravir or lamivudine, was approved by the U.S.


    Food and Drug Administration (FDA) in April.Dolutegravir and lamivudine are both ingredients in Dovato.. A new indication and longer-term safety and efficacy results from the GEMINI 1 and 2 trials were added to the Dovato product labelling in August with FDA approval.


    According to a research in the New England Journal of Medicine, lamivudine can effectively cure chronic hepatitis B patients who have cirrhosis or advanced fibrosis that has been verified histologically.For a duration of weeks, participants in the  were randomly randomised to either lamivudine or a placebo.



    • GlaxoSmithKline
    • Zydus Cadila
    • Cipla
    • Teva Pharmaceuticals
    • Sun Pharmaceutical Industries
    • Ranbaxy Laboratories



    1. How many Lamivudine are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Global Lamivudine and key vendor selection criteria
    3. Where is the Lamivudine manufactured? What is the average margin per unit?
    4. Market share of Global Lamivudine market manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Global Lamivudine in-house
    6. key predictions for next 5 years in Global Lamivudine market
    7. Average B-2-B Lamivudine market price in all segments
    8. Latest trends in Lamivudine market, by every market segment
    9. The market size (both volume and value) of the Lamivudine market in 2023-2030 and every year in between?
    10. Production breakup of Lamivudine market, by suppliers and their OEM relationship


    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2023-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2023-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2023-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2023-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
      Your Cart
      Your cart is emptyReturn to Shop